Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results

May 9, 2011 By Bio-Medicine.Org

SAN DIEGO, May 9, 2011 /PRNewswire/ — Orexigen®
Therapeutics, Inc. (Nasdaq:
OREX), a biopharmaceutical company focused on the treatment of
obesity, today announced financial results for the first quarter of
2011.  For the three months ended March 31, 2011, Orexigen
reported a net loss of $11.6 million, or $0.24 per share, as
compared to a net loss of $14.1 million, or $0.30 per share, for
the first quarter of 2010.  As of March 31, 2011, Orexigen had
$39.6 million in cash and cash equivalents and an additional $36.9
million in marketable securities, for a total of approximately
$76.6 million.

“Over the last several months, together with our partner,
Takeda, and our external advisors, we have been preparing for a
meeting with FDA to discuss a viable path forward for
Contrave®,” said Michael Narachi, president and CEO of
Orexigen. “We have submitted to the Agency a specific, innovative,
and robust proposal to assess cardiovascular risk and have
confirmed a meeting with the Agency later this quarter to discuss
our proposal.”

Total operating expenses for the first quarter of 2011 were
$13.3 million compared to $14.0 million for the first quarter of
2010. This decrease in operating expenses primarily reflects a
decrease in research and development expenses of $1.4 million
principally related to the reduction in costs incurred in
connection with the preparation for our NDA filing for Contrave in
the first quarter of 2011 as compared to same period in
2010. This overall decrease was partially offset by an
increase in general and administrative expenses principally related
to one-time corporate realignment costs.

Conference Call Today at 8:00 a.m. Eastern Time (5:00 a.m.
Pacific Time) The Orexigen management team will host a
teleconference and webcast to discuss the first quarter 2011
financial results and recent business highlights. The l

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech